Becampanel

Becampanel (INN) (code name AMP397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor (IC50 = 11 nM).[1][2][3][4] It was investigated as an anticonvulsant for the treatment of epilepsy by Novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials.[1][2][3][5]

Becampanel
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H11N4O7P
Molar mass330.193 g·mol−1
3D model (JSmol)

References
  1. John B. Taylor; D. J. Triggle (2007). Comprehensive medicinal chemistry II. Elsevier. p. 290. ISBN 978-0-08-044513-7.
  2. Kwan P, Brodie MJ (September 2007). "Emerging drugs for epilepsy". Expert Opin Emerg Drugs. 12 (3): 407–22. doi:10.1517/14728214.12.3.407. PMID 17874969. S2CID 27627114.
  3. Citraro R, Aiello R, Franco V, De Sarro G, Russo E (March 2014). "Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy". Expert Opin. Ther. Targets. 18 (3): 319–34. doi:10.1517/14728222.2014.874416. PMID 24387310. S2CID 1504490.
  4. World Health Organization (1988). International Nonproprietary Names (INN) for Pharmaceutical Substances. W.H.O. ISBN 9789240560369.
  5. Pathan SA, Jain GK, Akhter S, Vohora D, Ahmad FJ, Khar RK (September 2010). "Insights into the novel three 'D's of epilepsy treatment: drugs, delivery systems and devices". Drug Discov. Today. 15 (17–18): 717–32. doi:10.1016/j.drudis.2010.06.014. PMID 20603226.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.